




LISTING OF CLAIMS


CLAIMS 1-19 (CANCELED)

20- (currently amended) A compound of formula (I) :



5 wherein :

♦ A represents



wherein R₁ represents linear or branched (C₁-C₆)alkyl, linear or branched (C₂-C₆)alkenyl, linear or branched (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkyl-(C₁-C₆)alkyl in which the alkyl moiety may be linear or branched, aryl, or aryl-(C₁-C₆)alkyl in which the alkyl moiety may be linear or branched, ~~heteroaryl or heteroaryl~~ (C₄-C₆)alkyl in which the alkyl moiety may be linear or branched,

and R₂ represents hydrogen or linear or branched (C₁-C₆)alkyl,

it being possible, for R₁ and R₂ together to form a linear or branched alkylene chain having from 3 to 6 carbon atoms,

- 15 ♦ R₃ represents linear or branched (C₁-C₆)alkoxy,
- ♦ R₄ represents halogen, hydroxy, linear or branched (C₁-C₆)alkoxy or amino optionally substituted by one or two linear or branched (C₁-C₆)alkyl,
- ♦ p is 1, 2 or 3,

it being understood that :

- "aryl" denotes phenyl, naphthyl or biphenyl,
- "heteroaryl" denotes a mono- or bi-cyclic aromatic group having from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,

wherein the aryl and heteroaryl groups so defined may be substituted by from 1 to 3 groups
5 selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)alkoxy, hydroxy, carboxy, formyl, nitro, cyano, linear or branched polyhalo(C₁-C₆)alkyl, alkoxycarbonyl and halogen,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

21- (canceled)

10 22- (previously presented) A compound of Claim 20, wherein R₁ represents linear or branched (C₁-C₆)alkyl.

23- (previously presented) A compound of Claim 20, wherein R₁ represents (C₃-C₈)cyclo-alkyl.

15 24- (previously presented) A compound of Claim 20, wherein R₂ represents hydrogen.

25- (previously presented) A compound of Claim 20, wherein p is 2.

26- (previously presented) A compound of Claim 20, wherein R₃ represents methoxy.

27- (previously presented) A compound of Claim 20, wherein R₄ represents OH.

28- (previously presented) A compound of Claim 20, wherein R₄ represents OMe.

20 29- (previously presented) A compound of Claim 20, wherein R₄ represents NH₂.

30- (previously presented) A compound of Claim 20, wherein R₄ represents halogen.

31- (previously presented) A compound of Claim 20, wherein the -CH₂R₄ group is in the 3 position (meta) of the phenyl group.

32- (previously presented) A compound of Claim 20, which is selected from *N*-(2-{3-[3-(hydroxymethyl)phenyl]-7-methoxy-1-naphthyl}ethyl)acetamide, and addition salts thereof with a pharmaceutically-acceptable acid or base.

33- (previously presented) A compound of Claim 20, which is selected from *N*-(2-{3-[3-(aminomethyl)phenyl]-7-methoxy-1-naphthyl}ethyl)acetamide, and addition salts thereof with a pharmaceutically-acceptable acid or base.

34- (canceled)

35- (currently amended) A method of treating a living animal body, including a human, afflicted with a disorder of the melatonergic system selected from sleep disorders, stress, anxiety, seasonal affective disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, disorders associated with normal or pathological aging, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, sexual dysfunctions, and cancer, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 20 which is effective for alleviation of the disorder.

36- (canceled)

37- (previously presented) A pharmaceutical composition comprising as active principle an effective amount of a compound of Claim 20, together with one or more pharmaceutically-acceptable excipients or vehicles.

38- (canceled)

39- (canceled)

40- (canceled)